Note 3: Restructuring and Impairment Expenses continued Other PPE unrelated to restructuring activities The Group recorded impairment of $249m relating to PPE within the CSL Behring operating segment during the year ended 30 June 2026. The impairment arose following the decision to advance the Horizon 2 immunoglobulin yield improvement program in the U.S. As a result, certain assets, including assets under construction, are no longer expected to be utilised as originally planned and their recoverable amount was determined to be below carrying value. Further, the Group identified impairment indicators for certain CSL Seqirus PPE during the year ended 30 June 2026, including lower forecast demand associated with declining vaccination rates, and reduced capacity utilisation resulting from improved manufacturing yields. These factors decreased expected production volumes, leading to lower forecast cash flows and recoverable amounts for the affected assets. The Group recognised an impairment charge of $191m, reducing the carrying value of the affected assets to $577m at 30 June 2026. The recoverable amount of the affected assets remains most sensitive to assumptions regarding future operating costs along with revenues associated with pandemic preparedness arrangements, including the renewal of existing contracts as outlined in the table below. Future impairment reversals may also arise if changes in regulatory or market conditions result in manufacturing utilisation exceeding current forecasted demand. CSL Seqirus impacted PPE Operating cost indexation Pandemic preparedness demand US$m - 1% / 1% - 10% / + 10% Change in recoverable amount 107 / (121) (78) / 70 Impairment (reversal)/charge (107) / 121 78 / (70) The table below outlines the total impairment expenses split by segment and the nature of the related assets: Year ended 30 June 2026 (US$m) CSL Behring CSL Vifor3 CSL Seqirus R&D & Corporate Total Impairment of PPE and right-of-use assets related to restructuring activities(a) (Note 9) 10 — — 188 198 Impairment expenses related to restructuring (a) 10 — — 188 198 Impairment of PPE and right-of-use assets unrelated to restructuring activities (Note 9) 1,217 — 230 19 1,466 Impairment of intangible assets unrelated to restructuring activities (Note 8) 5 3,145 485 28 3,663 Impairment of goodwill (CSL Vifor CGU) (Note 8) — 1,700 — — 1,700 Impairment of other assets 24 — 28 52 Impairment expenses unrelated to restructuring (b) 1,246 4,845 715 75 6,881 Total impairment expenses 1,256 4,845 715 263 7,079 103 Notes to the Financial Statements 3 Following the impairments charges recognised during the year in respect of CSL Vifor intangible assets, the carrying value at 30 June 2026 includes IP attributable to commercialised products within the Iron Deficiency ($1,799m) and Nephrology - Dialysis ($622m) therapeutic areas. 103 CSL Limited Annual Report 2025/26
RkJQdWJsaXNoZXIy MjE2NDg3